07 Jan 2001

Eremfat® 150 (Eremfat® 150/-300/-450/-600 Filmtabletten) - Deutschland

Updated: 07 Jan 2001

Eremfat® 150 | -300 | -450 | -600; -Sirup; -i.v. 300 mg | -600 mg

Tuberkulose (in Komb. mit anderen Tuberkulosemitteln). Zur Kombinationsbehandl. bei Lepra u. Buruli ulcus (Erreger: Mycobacterium leprae, bzw. M. ulcerans). Meningokokken- Meningitis-Prophylaxe.

Eremfat® 150 Description, Presentation and Dosage

Eremfat® 150 Description

Eremfat® 150 Drug Class Description

Einzelstoffe

Eremfat® 150 Drug Description

1 Filmtbl. enth.: Rifampicin 150 mg/300 mg/450 mg/600 mg.

Eremfat® 150 Generic Name

Eremfat® 150/-300/-450/-600 Filmtabletten

Eremfat® 150 Presentation

Eremfat® 150 Presentation

Eremfat® 150/-300/-450/-600; -Sirup; -i.v. 300 mg/-600 mg

Eremfat® 150 Manufacturer

Fatol

Related Learning Zones

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Oral Anticoagulation Reversal Knowledge Centre

Oral Anticoagulation Reversal Knowledge Centre

The Oral Anticoagualtion Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. Content is arranged within illustrated and referenced sections including management of bleeding risk, oral anticoagulants, symposium highlights, key publication summaries and more.

This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.

This resource is not intended for healthcare professionals outside Europe.

Eremfat® 150 Dosage

Eremfat® 150 Adult Dosage

Poly(O-2-hydroxypropyl-O-methyl)cellulose, Croscarmellose-Natrium, Magnesiumstearat, Talkum, Farbstoffe: E 171, E 172, Crospovidon, Sorbitol.

Eremfat® 150 Child Dosage


Eremfat® Sirup Trockensirup
Zus.: 5 ml enth.: Rifampicin 100 mg.
Weit. Bestandteile: Saccharose 2,16 g, Natriumbenzoat (als Konservierungsmittel), Aromastoffe.

Eremfat® i.v. 300 mg/-600 mg Trockensubstanz u. Lösungsmittel
Zus.: 1 Inj.-Fl. enth.: Rifampicin-Natrium 308,2 mg mg/616,4 mg (entspr. 300 mg/600 mg Rifampicin).
Weit. Bestandteile: Natriumascorbat 5 mg/10 mg.

Eremfat® 150 Elderly Dosage

5 ml entspr. 0,18 BE.

Eremfat® 150 Precautions, Reactions and Contraindications

Eremfat® 150 Special Precautions

Eremfat® 150 Special Precautions

R 15

Eremfat® 150 Adverse Reactions

Eremfat® 150 Adverse Reactions

R 15

Related Drugs - Tropical Medicine

Back to top